uniQure (NASDAQ:QURE) Stock Price Up 8.3% – Here’s Why

uniQure N.V. (NASDAQ:QURE) was up 8.3% on Tuesday . The stock traded as high as $48.66 and last traded at $48.09. Approximately 456,705 shares traded hands during trading, a decline of 83% from the average session volume of 2,715,994 shares. The stock had previously closed at $44.39.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported encouraging early data from its AMT-260 gene therapy program in temporal lobe epilepsy, including meaningful seizure reductions in the first patients and no treatment-related serious adverse events, which supports optimism around its pipeline and growth prospects. Article Title
• Positive Sentiment: Additional coverage highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor enthusiasm for AMT-260’s early clinical promise. Article Title
• Positive Sentiment: Analyst commentary has also been supportive, with recent upgrades and higher price targets adding to the bullish backdrop for QURE. Article Title
• Neutral Sentiment: uniQure announced preliminary Phase I/IIa data for AMT-260, a routine but important milestone for a development-stage biotech company. Article Title
• Negative Sentiment: The company launched a $150 million underwritten public offering, with a possible $22.5 million greenshoe, which may pressure the stock because it could dilute existing shareholders. Article Title
• Negative Sentiment: Recent insider sales by CEO Matthew Kapusta and directors Jack Kaye and Madhavan Balachandran may weigh on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on QURE shares. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. The Goldman Sachs Group lifted their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. Wolfe Research began coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Finally, Chardan Capital increased their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $58.92.

uniQure Stock Performance

The stock has a market cap of $2.98 billion, a price-to-earnings ratio of -13.56 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a fifty day simple moving average of $25.30 and a 200-day simple moving average of $22.30.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 41,671 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $50.00, for a total transaction of $2,083,550.00. Following the completion of the sale, the chief executive officer directly owned 521,795 shares of the company’s stock, valued at $26,089,750. The trade was a 7.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David D. Meek sold 1,993 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director directly owned 39,747 shares in the company, valued at approximately $1,075,553.82. The trade was a 4.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 324,134 shares of company stock worth $12,778,769. Corporate insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC grew its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. Orbimed Advisors LLC grew its stake in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in uniQure during the 4th quarter worth approximately $33,062,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.